(ASND) Ascendis Pharma AS - Ratings and Ratios

Exchange: NASDAQ • Country: Denmark • Currency: USD • Type: Common Stock • ISIN: US04351P1012

TransCon, Hormone, Parathyroid, Oncology, Rare

Stock: Biotechnology
Age 11y
MCap 12,576m
Avg Vol 483K (103M USD)
Beta 0.310
Volatility 40.49%

EPS (Earnings per Share)

EPS (Earnings per Share) of ASND over the last years for every Quarter: "2020-12": -2.64, "2021-03": -1.17, "2021-06": -2.5, "2021-09": -1.47, "2021-12": -1.87, "2022-03": -2.21, "2022-06": -1.46, "2022-09": -3.03, "2022-12": -3.7, "2023-03": -1.98, "2023-06": -2.16, "2023-09": -2.88, "2023-12": -1.54, "2024-03": -2.3, "2024-06": -2.11, "2024-09": -1.72, "2024-12": -0.64, "2025-03": -1.58, "2025-06": -0.64, "2025-09": -1, "2025-12": 0,
EPS CAGR: 25.15%
EPS Trend: 73.2%
Last SUE: 0.18
Qual. Beats: 0

Revenue

Revenue of ASND over the last years for every Quarter: 2020-12: 0.535, 2021-03: 0.746, 2021-06: 1.022, 2021-09: 1.113, 2021-12: 4.897, 2022-03: 6.828, 2022-06: 6.16, 2022-09: 15.29, 2022-12: 22.896, 2023-03: 33.589, 2023-06: 47.393, 2023-09: 48.034, 2023-12: 137.702, 2024-03: 95.894, 2024-06: 35.998, 2024-09: 57.833, 2024-12: 173.916, 2025-03: 100.954, 2025-06: 158.045, 2025-09: 213.634, 2025-12: null,
Rev. CAGR: 173.69%
Rev. Trend: 89.2%
Last SUE: 0.03
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 40.5%
Value at Risk 5%th 58.2%
Relative Tail Risk -12.57%
Reward TTM
Sharpe Ratio 1.58
Alpha 79.61
CAGR/Max DD 0.56
Character TTM
Hurst Exponent 0.383
Beta 0.310
Beta Downside 0.250
Drawdowns 3y
Max DD 43.62%
Mean DD 13.20%
Median DD 12.03%

Description: ASND Ascendis Pharma AS January 02, 2026

Ascendis Pharma A/S (NASDAQ: ASND) is a Denmark-based biopharmaceutical firm that develops long-acting, TransCon-platform therapies for unmet endocrine and oncology indications. Its marketed products include SKYTROFA for pediatric growth-hormone deficiency and YORVIPATH, a once-daily injection for adult chronic hypoparathyroidism, while a pipeline of three rare-disease endocrinology candidates and several oncology programs remain in clinical development.

Key recent metrics: as of Q2 2024, Ascendis reported cash and equivalents of approximately $210 million, extending its runway to late 2025; SKYTROFA generated $12 million in net sales in 2023, reflecting a 35 % YoY growth driven by expanding pediatric endocrinology adoption in Europe and the U.S.; the global market for growth-hormone therapies is projected to reach $7 billion by 2028, providing a favorable macro-trend for the company’s core franchise. Additionally, the biotech sector’s R&D tax credit environment in Denmark and the U.S. continues to support cash-flow efficiency for firms at Ascendis’s stage.

For a deeper, data-driven assessment of Ascendis’s valuation and risk profile, you may find ValueRay’s analyst tools worth exploring.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income: -232.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.10 > 0.02 and ΔFCF/TA 14.28 > 1.0
NWC/Revenue: 4.84% < 20% (prev 41.32%; Δ -36.48% < -1%)
CFO/TA -0.09 > 3% & CFO -106.7m > Net Income -232.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.03 > 1.5 & < 3
Outstanding Shares: last quarter (61.0m) vs 12m ago 4.14% < -2%
Gross Margin: 86.80% > 18% (prev 0.85%; Δ 8595 % > 0.5%)
Asset Turnover: 57.51% > 50% (prev 29.94%; Δ 27.57% > 0%)
Interest Coverage Ratio: -0.98 > 6 (EBITDA TTM -133.2m / Interest Expense TTM 154.2m)

Altman Z'' -10.49

A: 0.03 (Total Current Assets 1.02b - Total Current Liabilities 986.5m) / Total Assets 1.15b
B: -2.34 (Retained Earnings -2.71b / Total Assets 1.15b)
C: -0.13 (EBIT TTM -150.5m / Avg Total Assets 1.12b)
D: -2.03 (Book Value of Equity -2.70b / Total Liabilities 1.33b)
Altman-Z'' Score: -10.49= D

Beneish M -1.30

DSRI: 2.06 (Receivables 134.7m/33.1m, Revenue 646.5m/327.4m)
GMI: 0.98 (GM 86.80% / 84.82%)
AQI: 1.48 (AQ_t 0.03 / AQ_t-1 0.02)
SGI: 1.97 (Revenue 646.5m / 327.4m)
TATA: -0.11 (NI -232.9m - CFO -106.7m) / TA 1.15b)
Beneish M-Score: -1.30 = D

ValueRay F-Score (Strict, 0-100) 38.84

1. Piotroski: 3.0pt
2. FCF Yield: -1.02%
3. FCF Margin: -17.35%
4. Debt/Equity: -4.67
5. Debt/Ebitda: data missing
6. ROIC - WACC: -24.63%
7. RoE: 141.8%
8. Revenue Trend: 89.23%
9. EPS Trend: 73.21%

What is the price of ASND shares?

As of January 24, 2026, the stock is trading at USD 235.39 with a total of 1,247,222 shares traded.
Over the past week, the price has changed by +14.36%, over one month by +12.50%, over three months by +17.10% and over the past year by +84.63%.

Is ASND a buy, sell or hold?

Ascendis Pharma AS has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy ASND.
  • Strong Buy: 12
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ASND price?

Issuer Target Up/Down from current
Wallstreet Target Price 262.9 11.7%
Analysts Target Price 262.9 11.7%
ValueRay Target Price 292.6 24.3%

ASND Fundamental Data Overview January 19, 2026

Market Cap EUR = 10.75b (12.58b USD * 0.8552 USD.EUR)
P/E Forward = 48.3092
P/S = 19.4507
P/B = 14.5547
Revenue TTM = 646.5m EUR
EBIT TTM = -150.5m EUR
EBITDA TTM = -133.2m EUR
Long Term Debt = 331.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 482.3m EUR (from shortTermDebt, last quarter)
Debt = 813.6m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 274.6m EUR (from netDebt column, last quarter)
Enterprise Value = 11.03b EUR (10.75b + Debt 813.6m - CCE 539.1m)
Interest Coverage Ratio = -0.98 (Ebit TTM -150.5m / Interest Expense TTM 154.2m)
EV/FCF = -98.34x (Enterprise Value 11.03b / FCF TTM -112.2m)
FCF Yield = -1.02% (FCF TTM -112.2m / Enterprise Value 11.03b)
FCF Margin = -17.35% (FCF TTM -112.2m / Revenue TTM 646.5m)
Net Margin = -36.03% (Net Income TTM -232.9m / Revenue TTM 646.5m)
Gross Margin = 86.80% ((Revenue TTM 646.5m - Cost of Revenue TTM 85.3m) / Revenue TTM)
Gross Margin QoQ = 89.54% (prev 80.10%)
Tobins Q-Ratio = 9.55 (Enterprise Value 11.03b / Total Assets 1.15b)
Interest Expense / Debt = 2.42% (Interest Expense 19.7m / Debt 813.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -118.9m (EBIT -150.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.03 (Total Current Assets 1.02b / Total Current Liabilities 986.5m)
Debt / Equity = -4.67 (negative equity) (Debt 813.6m / totalStockholderEquity, last quarter -174.1m)
Debt / EBITDA = -2.06 (negative EBITDA) (Net Debt 274.6m / EBITDA -133.2m)
Debt / FCF = -2.45 (negative FCF - burning cash) (Net Debt 274.6m / FCF TTM -112.2m)
Total Stockholder Equity = -164.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.72% (Net Income -232.9m / Total Assets 1.15b)
RoE = 141.8% (negative equity) (Net Income TTM -232.9m / Total Stockholder Equity -164.3m)
RoCE = -90.08% (EBIT -150.5m / Capital Employed (Equity -164.3m + L.T.Debt 331.4m))
RoIC = -17.93% (negative operating profit) (NOPAT -118.9m / Invested Capital 663.2m)
WACC = 6.70% (E(10.75b)/V(11.57b) * Re(7.06%) + D(813.6m)/V(11.57b) * Rd(2.42%) * (1-Tc(0.21)))
Discount Rate = 7.06% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 3.79%
Fair Price DCF = unknown (Cash Flow -112.2m)
EPS Correlation: 73.21 | EPS CAGR: 25.15% | SUE: 0.18 | # QB: 0
Revenue Correlation: 89.23 | Revenue CAGR: 173.7% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.43 | Chg30d=+0.029 | Revisions Net=+1 | Analysts=8
EPS next Year (2026-12-31): EPS=3.47 | Chg30d=+0.112 | Revisions Net=+2 | Growth EPS=+205.1% | Growth Revenue=+82.9%

Additional Sources for ASND Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle